Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Neurology

Validation & Orientation for Atypical Rett Syndrome

At a Glance

Atypical Rett syndrome describes a child who shares features of classic Rett but does not meet all standard clinical criteria. With advances in testing, many atypical cases are now diagnosed as distinct genetic conditions, such as CDKL5 Deficiency Disorder or FOXG1 Syndrome, to guide targeted care.

Receiving a diagnosis of atypical Rett syndrome can feel like being dropped into an unfamiliar world without a map. It is normal to feel overwhelmed, confused, or even grieving for the path you imagined for your child [1][2]. This diagnosis often follows a long and exhausting “diagnostic odyssey” of testing and uncertainty [1][3].

While the news is heavy, a diagnosis is also a turning point. It marks the end of searching for “why” and the beginning of a targeted plan for “how” to best support your child [4][1].

Understanding the “Atypical” Label

In the medical world, “atypical” simply means your child shares many features with classic Rett syndrome—a rare neurodevelopmental disorder affecting about 1 in 10,000 to 20,000 girls—but they do not fit all the rigid clinical rules for that specific category [5][6].

A child with atypical Rett syndrome may have symptoms that are milder or more severe than classic cases [6][7]. They might skip the period of “regression” (loss of skills) seen in classic Rett, or they might develop symptoms like seizures much earlier [8][9].

A Shift Toward Genetic Precision

The way doctors name these conditions is changing. For years, “Atypical Rett” was used as a broad “umbrella” for many different genetic conditions [9][10]. Today, as genetic testing becomes more precise, the medical field is moving away from this umbrella and toward naming conditions by the specific gene mutation involved [9][11]:

  • CDKL5 Deficiency Disorder (CDD): Formerly called the “early-onset seizure variant” of Rett, this is now recognized as its own distinct disorder [9][8].
  • FOXG1 Syndrome: Once called the “congenital variant,” it is now viewed as a separate entity with its own unique set of challenges [9][12].
  • MECP2 Variants: Some children have mutations in the MECP2 gene (the same gene as classic Rett) but their specific mutation leads to an “atypical” presentation [5].

Identifying the exact gene mutation is critical because it helps your care team provide a more accurate “roadmap” for your child’s future [4][9].

Three Stabilizing Facts

When the future feels uncertain, grounding yourself in these facts can help provide a sense of stability:

  1. This is Genetic, Not Your Fault: These conditions are caused by random changes in DNA. Nothing you did—or didn’t do—during pregnancy or early childhood caused this mutation [13][14].
  2. We Are Entering the Era of Precision Medicine: Research has shifted from just managing symptoms to developing targeted therapies, such as gene replacement and protein strategies [15][16]. Treatments have already been approved to help improve symptoms for specific mutations [17][18].
  3. A Diagnosis Opens Doors: While the name is scary, it provides the “key” to specialized services, insurance coverage for therapies, and a community of families who understand exactly what you are going through [19][20].

The Impact on the Whole Family

It is essential to acknowledge that an intensive caregiving journey affects the entire family unit. Parent burnout, financial stress, and the emotional impact on siblings are real and common challenges [21]. Finding support groups, advocating for respite care, and recognizing your own limits are not signs of weakness, but necessary steps to ensure you can continue to care for your child effectively.

Navigating Certainty vs. Uncertainty

It is helpful to clarify what doctors can tell you now versus what will take time to understand:

What is Certain What is Uncertain
The specific genetic mutation identified in testing [13]. The exact pace of development for your individual child [2].
That your child will need a multidisciplinary care team (specialists in neurology, therapy, etc.) [22]. How your child will respond to specific new treatments or trials [16].
That you are part of a rare disease community with dedicated advocacy groups for support [23]. The full long-term outlook, as medical research is advancing rapidly every year [15].

Your child is more than a diagnosis. While the genetic code provides a framework, it does not define your child’s personality, their smile, or the unique way they will connect with your family. Empowering yourself with information is the first step in advocating for the best possible quality of life for them [24][21].

Common questions in this guide

What does an atypical Rett syndrome diagnosis mean?
An atypical diagnosis means your child shares many features with classic Rett syndrome but doesn't meet all the rigid clinical rules. Symptoms may be milder or more severe, and your child might develop symptoms earlier or skip the typical period of skill regression.
Are CDKL5 and FOXG1 the same as atypical Rett syndrome?
Historically, they were grouped under the atypical Rett syndrome umbrella. Today, as genetic testing has improved, they are recognized as distinct disorders called CDKL5 Deficiency Disorder and FOXG1 Syndrome, each with its own specific care plan.
Did I do something to cause my child's atypical Rett syndrome?
No. These conditions are caused by random, unpredictable changes in DNA. Nothing you did or didn't do during pregnancy or early childhood caused this genetic mutation.
How does knowing the specific genetic mutation help my child?
Identifying the exact gene mutation helps your multidisciplinary care team anticipate specific health issues and developmental milestones. It also opens doors to specialized clinics, support groups, and potentially targeted therapies.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific genetic mutation was identified in my child's test results?
  2. 2.Does my child's condition fall under a specific gene-disorder name like CDKL5 Deficiency Disorder or FOXG1 Syndrome?
  3. 3.How does this atypical diagnosis change our expectations for my child’s developmental milestones compared to 'classic' Rett syndrome?
  4. 4.What are the most common health issues we should be monitoring for based on this specific genetic variant?
  5. 5.Can you refer us to a multidisciplinary care team or a specialized clinic that has experience with atypical cases?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Neurodevelopmental disorder: Hao-Fountain syndrome with USP7 mutation-a case report.

    Rafeienejad F, Keyhani E, Akbarfahimi N, Nouri N

    Journal of medical case reports 2025; (19(1)):363 doi:10.1186/s13256-025-05403-y.

    PMID: 40707997
  2. 2

    Family Resilience and Its Association with Psychosocial Adjustment of Children with Chronic Illness: A Latent Profile Analysis.

    Dong C, Wu Q, Pan Y, et al.

    Journal of pediatric nursing 2021; (60()):e6-e12 doi:10.1016/j.pedn.2021.02.010.

    PMID: 33622641
  3. 3

    Novel WAC gene variant identified in the first documented case of DeSanto-Shinawi Syndrome in India.

    Dwivedi A, Chauhan L, Kumar P, et al.

    Molecular and cellular pediatrics 2025; (12(1)):7 doi:10.1186/s40348-025-00193-1.

    PMID: 40347397
  4. 4

    An overview of genetic mutations in Aicardi-Goutières syndrome in Iranian population.

    Khalilian S, Fathi M, Miryounesi M, Ghafouri-Fard S

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2025; (46(2)):999-1007 doi:10.1007/s10072-024-07824-x.

    PMID: 39470906
  5. 5

    Epilepsy and genetic in Rett syndrome: A review.

    Operto FF, Mazza R, Pastorino GMG, et al.

    Brain and behavior 2019; (9(5)):e01250 doi:10.1002/brb3.1250.

    PMID: 30929312
  6. 6

    Anthropometric Measures Correspond with Functional Motor Outcomes in Females with Rett Syndrome.

    Motil KJ, Geerts S, Annese F, et al.

    The Journal of pediatrics 2022; (244()):169-177.e3 doi:10.1016/j.jpeds.2022.01.009.

    PMID: 35063470
  7. 7

    The array of clinical phenotypes of males with mutations in Methyl-CpG binding protein 2.

    Neul JL, Benke TA, Marsh ED, et al.

    American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2019; (180(1)):55-67 doi:10.1002/ajmg.b.32707.

    PMID: 30536762
  8. 8

    Phenotypic manifestations between male and female children with CDKL5 mutations.

    Liang JS, Huang H, Wang JS, Lu JF

    Brain & development 2019; (41(9)):783-789 doi:10.1016/j.braindev.2019.05.003.

    PMID: 31122804
  9. 9

    Comparison of Core Features in Four Developmental Encephalopathies in the Rett Natural History Study.

    Cutri-French C, Armstrong D, Saby J, et al.

    Annals of neurology 2020; (88(2)):396-406 doi:10.1002/ana.25797.

    PMID: 32472944
  10. 10

    Clinical and biological progress over 50 years in Rett syndrome.

    Leonard H, Cobb S, Downs J

    Nature reviews. Neurology 2017; (13(1)):37-51 doi:10.1038/nrneurol.2016.186.

    PMID: 27934853
  11. 11

    Current developments in the genetics of Rett and Rett-like syndrome.

    Ehrhart F, Sangani NB, Curfs LMG

    Current opinion in psychiatry 2018; (31(2)):103-108 doi:10.1097/YCO.0000000000000389.

    PMID: 29206688
  12. 12

    FOXG1 Mutation is a Low-Incidence Genetic Cause in Atypical Rett Syndrome.

    Byun CK, Lee JS, Lim BC, et al.

    Child neurology open 2015; (2(1)):2329048X14568151 doi:10.1177/2329048X14568151.

    PMID: 28503589
  13. 13

    MECP2 Mutations in the Rett Syndrome Patients from South India.

    Anitha A, Poovathinal SA, Viswambharan V, et al.

    Neurology India 2022; (70(1)):249-253 doi:10.4103/0028-3886.338714.

    PMID: 35263890
  14. 14

    An Atypical Rett Syndrome Phenotype Due to a Novel Missense Mutation in CACNA1A.

    Epperson MV, Haws ME, Standridge SM, Gilbert DL

    Journal of child neurology 2018; (33(4)):286-289 doi:10.1177/0883073818754987.

    PMID: 29366381
  15. 15

    Disease-modifying therapies for Rett syndrome: a review for neurologists.

    Samanta D

    Frontiers in neurology 2026; (17()):1766679 doi:10.3389/fneur.2026.1766679.

    PMID: 41641323
  16. 16

    Psychometric Assessment of the Rett Syndrome Caregiver Assessment of Symptom Severity (RCASS).

    Raspa M, Gwaltney A, Bann C, et al.

    Journal of autism and developmental disorders 2025; (55(3)):997-1009 doi:10.1007/s10803-024-06238-0.

    PMID: 38438817
  17. 17

    Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study.

    Percy AK, Neul JL, Benke TA, et al.

    Med (New York, N.Y.) 2024; (5(9)):1178-1189.e3 doi:10.1016/j.medj.2024.05.018.

    PMID: 38917793
  18. 18

    Trofinetide: First Approval.

    Keam SJ

    Drugs 2023; (83(9)):819-824 doi:10.1007/s40265-023-01883-8.

    PMID: 37191913
  19. 19

    Perceived Benefits and Factors that Influence the Ability to Establish and Maintain Patient Support Groups in Rare Diseases: A Scoping Review.

    Delisle VC, Gumuchian ST, Rice DB, et al.

    The patient 2017; (10(3)):283-293 doi:10.1007/s40271-016-0213-9.

    PMID: 28004275
  20. 20

    Collaboration between patient organisations and a clinical research sponsor in a rare disease condition: learnings from a community advisory board and best practice for future collaborations.

    Roennow A, Sauvé M, Welling J, et al.

    BMJ open 2020; (10(12)):e039473 doi:10.1136/bmjopen-2020-039473.

    PMID: 33328257
  21. 21

    Sleep Problems and Clinical Severity in Rett Syndrome.

    Peters SU, Fu C, Shelton AR, et al.

    Journal of child neurology 2026; (41(2)):163-171 doi:10.1177/08830738251347561.

    PMID: 40567120
  22. 22

    Evidence-Based Physical Therapy for Individuals with Rett Syndrome: A Systematic Review.

    Fonzo M, Sirico F, Corrado B

    Brain sciences 2020; (10(7)) doi:10.3390/brainsci10070410.

    PMID: 32630125
  23. 23

    Utilization and Perception of Peer-Support After Lower Limb Loss in the United States: Potential Benefits on Mobility Outcomes.

    Lee SP, Maluotoga M, Thind R, et al.

    Archives of physical medicine and rehabilitation 2024; (105(5)):939-946.e3 doi:10.1016/j.apmr.2023.12.009.

    PMID: 38242299
  24. 24

    The Changing Face of Survival in Rett Syndrome and MECP2-Related Disorders.

    Tarquinio DC, Hou W, Neul JL, et al.

    Pediatric neurology 2015; (53(5)):402-11.

    PMID: 26278631

This page provides educational information about atypical Rett syndrome for parents and caregivers. Always consult your pediatric neurologist or geneticist for medical advice tailored to your child's specific diagnosis.

Get notified when new evidence is published on Atypical Rett syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.